There are currently 42 active clinical trials seeking participants for Brain Metastases research studies. The states with the highest number of trials for Brain Metastases participants are Michigan, California, New York and North Carolina.
Development of MRF for Characterization of Brain Tumors After Radiotherapy
NCT06101069
Recruiting
The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participan... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
11/18/2024
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio +1 locations
Conditions: Brain Tumor, Brain Necrosis, Brain Metastases
Register for Updates
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
NCT05692635
Recruiting
The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Brain Metastases, Nonsmall Cell Lung Cancer Stage III
Register for Updates
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
NCT05064280
Recruiting
This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and solid tumor types other than TNBC and NSCLC. Cohort 3 will be comprised of solid tumor types with established (e.g., renal cell carcinoma \[RCC\], endometrial cancer) or p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Brain Metastases, Tumor
Register for Updates
Neurocognitive Decline in Patients With Brain Metastases
NCT03508752
Recruiting
The phase I component of the study is to identify maximal tolerated dose (MTD). The phase II is to evaluate neurocognitive decline.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Brain Metastases
Register for Updates
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391
Recruiting
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +84 locations
Conditions: Brain Metastases
Register for Updates
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT04923542
Recruiting
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Brain Metastases, HR+ Metastatic Breast Cancer
Register for Updates
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
NCT05673928
Recruiting
To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Solid Tumor, Brain Metastases
Register for Updates
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
NCT04365374
Recruiting
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: HonorHeath Scottsdale Osborn Medical Center, Phoenix, Arizona +35 locations
Conditions: Brain Metastases
Register for Updates
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib
NCT05323955
Recruiting
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. They will receive local therapy with stereotactic radiosurgery ± surgical resection if indicated followed by enrollment. Patients will continue standard of care trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib. Hormone receptor positive patients requiring endocrine therapy should con... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: University of California San Francisco, San Francisco, California +7 locations
Conditions: Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Register for Updates
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
NCT06209567
Recruiting
The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: High-grade Glioma, Brain Metastases, Brain Metastases, Adult
Register for Updates
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
NCT02390518
Recruiting
This is a Phase I dose escalation and expansion trial. The purpose of this study is to determine the maximum tolerated dose of radiation received during stereotactic radiosurgery in patients with brain metastases who have never received radiation to the brain before.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Brain Metastases
Register for Updates
MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases
NCT04246879
Recruiting
The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Duke University Health System, Durham, North Carolina
Conditions: Brain Metastases
Register for Updates